EnGeneIC Pty Ltd
105 Delhi Road, North Ryde
Sydney
New South Wales
2113
Tel: 612-9878-5456
Fax: 612-9878-5922
Email: jluthard@engeneic.com
25 articles about EnGeneIC Pty Ltd
-
EnGeneIC granted FDA “Fast-Track” Designation for Novel Armed Nanocell Drug Conjugate (ANDC) Pancreatic Cancer Therapeutic
12/8/2023
EnGeneIC, an innovative biopharmaceutical company leading the field of armed antibody therapeutics for oncology, has achieved a significant milestone with the granting of FDA “Fast-Track” designation for its pancreatic cancer therapeutic.
-
EnGeneIC’s breakthrough Armed Nanocell Drug Conjugate (ANDC) treatment shows promising results in Pancreatic cancer patients who have run out of treatment options
11/27/2023
EnGeneIC, a pioneer in personalised cancer therapeutics, announces the publication of its clinical trial results in peer reviewed prestigious journal “Clinical Cancer Research”, published by the American Association for Cancer Research.
-
Italfarmaco is making headway against DMD as it announced positive results from a Phase III study, Clover's homologous booster against Omicron increases antibodies, and much more.
-
Australian biotech, EnGeneIC, develops world-first nanocellular anti-COVID-19 vaccine that defeats mutant viruses and stimulates a broad anti-viral response
9/8/2021
EnGeneIC Limited, an Australian, Sydney-based biotechnology company, has developed a globally unique nanocellular technology that in pre-clinical animal studies has been shown to stimulate a broad and powerful anti-COVID-19 immune response and also neutralises the known mutant COVID-19 viruses of concern, particularly the delta variant.
-
EnGeneIC Announces Acceptance of Abstract to the Annual Meeting of the American Society of Clinical Oncology 2020
6/1/2020
Abstract Demonstrates Promising Early Results from Phase I/IIa study in Patients with Recurrent, Metastatic Pancreatic Cancer
-
EnGeneIC Novel Oncology-Focused Nanotechnology Featured in InsightsCare
2/12/2020
NEW YORK and SYDNEY , Feb. 12, 2020 /PRNewswire/ -- EnGeneIC Limited , a clinical-stage biopharmaceutical company advancing its proprietary EDV™ nanocell platform for targeted cyto-immunotherapy in cancer, today announced that the Company was featured in the publication InsightsCare
-
EnGeneIC Wins Innovation Award from Australian Financial Review
8/9/2019
Named Most Innovative Healthcare Company of 2019 for its Nanocell Platform for Targeted Cyto-Immunotherapy in Cancer Treatment
-
EnGeneIC Announces First Patients with Advanced-Stage Pancreatic Cancer Dosed in Phase 1/2a Clinical Study of Targeted Cytotoxic Immunotherapy
5/9/2019
EnGeneIC Limited announced that the first four patients have been dosed in a Phase 1/2a study using the Company's tumor-targeting, immunogenic EDVs™ to deliver a cytotoxic drug payload directly to tumors of patients who have exhausted curative treatment options.
-
EnGeneIC Pty Ltd Announces Publication In The Lancet Oncology Of First Clinical Study Employing EDV Nanocell Platform to Enable microRNA Replacement Therapy
9/5/2017
-
EnGeneIC Pty Ltd Doses First Patient In U.S. Phase 1 Clinical Study Of Targeted EDV Nanocells In Recurrent Glioblastoma Multiforme
3/21/2017
-
EnGeneIC Pty Ltd Receives FDA Orphan Drug Designation For Targeted EDV Nanocells To Treat Glioblastoma Multiforme
3/2/2017
-
EnGeneIC Pty Ltd Enters Into Research Collaboration With Takeda To Develop EDV-Based Immunomodulatory Therapies For Oncology
10/10/2016
-
EnGeneIC Pty Ltd's Joint-CEO And Co-Founder, Jennifer Macdiarmid, Ph.D., Recognized In Innovation Category In The Australian Financial Review And Westpac 100 Women Of Influence Awards For 2016
10/4/2016
-
EnGeneIC Pty Ltd Named One Of Science Meets Business Top 25 Australian Research And Development Spin-Off Companies
3/10/2016
-
EnGeneIC Pty Ltd To Present At BIO CEO & Investor Conference 2016
2/3/2016
-
EnGeneIC Pty Ltd Strengthens Board Of Directors To Support U.S. Expansion
1/25/2016
-
EnGeneIC Pty Ltd To Present At The Stifel 2015 Healthcare Conference
11/11/2015
-
EnGeneIC Pty Ltd To Initiate U.S. Phase 1 Clinical Study Using Targeted EDV Nanocells To Treat Advanced Glioma Patients
9/16/2015
-
EnGeneIC Pty Ltd To Present At Biotechnology Industry Organization (BIO) CEO & Investor Conference 2015
2/4/2015
-
EnGeneIC Pty Ltd Completes $10 Million Series B Financing Led By U.S. Institutional Investor
1/6/2015